Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 075453
Company: IVAX SUB TEVA PHARMS
Company: IVAX SUB TEVA PHARMS
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
DOXAZOSIN MESYLATE | DOXAZOSIN MESYLATE | EQ 1MG BASE | TABLET;ORAL | Discontinued | None | No | No |
DOXAZOSIN MESYLATE | DOXAZOSIN MESYLATE | EQ 2MG BASE | TABLET;ORAL | Discontinued | None | No | No |
DOXAZOSIN MESYLATE | DOXAZOSIN MESYLATE | EQ 4MG BASE | TABLET;ORAL | Discontinued | None | No | No |
DOXAZOSIN MESYLATE | DOXAZOSIN MESYLATE | EQ 8MG BASE | TABLET;ORAL | Discontinued | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
10/18/2000 | ORIG-1 | Approval |
Letter (PDF)
Letter (PDF) |
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/75453ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/75453TA.pdf |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
11/29/2005 | SUPPL-17 | Labeling |
Label is not available on this site. |
||
07/29/2002 | SUPPL-9 | Manufacturing (CMC)-Facility |
Label is not available on this site. |
||
12/11/2002 | SUPPL-6 | Manufacturing (CMC)-Packaging |
Label is not available on this site. |
||
12/11/2002 | SUPPL-5 | Labeling |
Label is not available on this site. |
||
12/11/2002 | SUPPL-4 | Manufacturing (CMC)-Facility |
Label is not available on this site. |
||
12/11/2002 | SUPPL-3 | Manufacturing (CMC)-Facility |
Label is not available on this site. |
||
08/28/2002 | SUPPL-2 | Labeling |
Label is not available on this site. |
||
08/28/2002 | SUPPL-1 | Manufacturing (CMC)-Packaging |
Label is not available on this site. |